Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus. Issue 4 (4th January 2018)

• Record Type: Journal Article
• Authors: Tago, Motoko; Oyama, Jun‐ichi; Sakamoto, Yoshiko; Shiraki, Aya; Uchida, Fumi; Chihara, Atsuko; Ikeda, Hideo; Kuroki, Shigetaka; Gondo, Shigeki; Iwamoto, Taketo; Uchida, Yasufumi; Node, Koichi
• Is Part Of: Geriatrics and gerontology international. Volume 18:Issue 4(2018)
• Page Start: 631
• Page End: 639
• Publication Date: 2018-01-04
• Subjects: blood pressure -- body mass index -- cardiovascular risks -- dipeptidyl peptidase‐4 inhibitor -- renal function; Geriatrics -- Periodicals; Gerontology -- Periodicals; Geriatrics -- Japan -- Periodicals; Gerontology -- Japan -- Periodicals; 618.97
• DOI: 10.1111/ggi.13235
• Languages: English
• ISSNs: 1444-1586

Abstract

Abstract : Aim: The aim of the present study was to assess the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus. Methods: A total of 188 patients were enrolled who had type 2 diabetes mellitus with poor glycemic profiles (hemoglobin A1c [HbA1c] ≥6.2%). Patients were assigned to one of three age groups (<65, 65–74 and ≥75 years) and received 50–100 mg of sitagliptin daily for 12 months. Changes in HbA1c classified by age and body mass index (BMI) were assessed in addition to physiological parameters. Results: Mean HbA1c decreased significantly in all age groups (<65 years 8.01 ± 1.59% to 7.29 ± 1.23%; 65–74 years 7.61 ± 1.11% to 7.05 ± 0.99%; ≥75 years 7.21 ± 0.87% to 6.74 ± 0.96%). Reductions in HbA1c were not significantly different among age groups ( P = 0.324). In older patients aged 65–74 years and ≥75 years, HbA1c decreased significantly in lean (BMI <25 kg/m 2 ) patients (7.52 ± 1.10% to 6.99 ± 1.08%; P < 0.001) and in obese (BMI ≥25 kg/m 2 ) patients (7.25% ± 0.90% to 6.86% ± 0.86%; P = 0.015); the changes in HbA1c were not significantly different between the lean and the obese groups ( P = 0.943). Adverse events occurred in 12 patients (10.3%) aged ≥65 years, although there was no significant difference among the three age groups. Conclusions: Sitagliptin treatment offers elderly patients aged ≥65 years efficacious and safe reductions in HbA1c values regardless of BMI.Geriatr Gerontol Int 2018; 18: 631–639 .